Aurora Cannabis Re-Affirms FY27 Q2 Guidance For Sequential Growth In Quarterly Net Revenue And Adjusted EBITDA

Aurora Cannabis Inc. has reaffirmed its guidance for fiscal year 2027 Q2, anticipating sequential growth in quarterly net revenue and adjusted EBITDA. The company expects incremental contributions from the Safari Flower Company following its EU-GMP certification in July. Aurora is experiencing strong performance in Germany and Poland, where it holds the #1 market share by revenue in Poland, and is expanding in the UK through the acquisition of Internode Pharma and HAP Pharma Limited.